Agripnidis Thibault, Ruimy Alexis, Panneau Julien, Nguyen Johanna, Nail Vincent, Tradi Farouk, Marx Thierry, Haffner Aurélie, Brige Pauline, Haumont Raphaël, Guillet Benjamin, Vidal Vincent
Interventional Radiology Section, Department of Medical Imaging, University Hospital Timone, AP-HM, 264 Rue Saint-Pierre, 13005, Marseille, France.
LIIE, Aix Marseille University, Marseille, France.
Cardiovasc Intervent Radiol. 2025 Feb;48(2):258-264. doi: 10.1007/s00270-024-03877-9. Epub 2024 Oct 15.
Evaluate the safety and efficacy of an eco-friendly permanent agar-agar-based embolization agent (ABEA) (EmboBio®) for intra-arterial use.
Six pigs embolized with one ABEA torpedo (6 lower polar renal and 6 lumbar arteries) and one coil (6 lower polar renal and 6 lumbar arteries). Technical success was defined as a complete occlusion with no residual flow in DSA. Short-term endpoints included safety (non-targeted embolization), ease of use (embolization preparation time, occlusion time), and DSA controls at day 7, month 1, and month 3. Tissue reaction was assessed via [18F]-FDG PET/CT at month 2 and histological study at month 3.
ABEA torpedoes achieved immediate and persistent occlusion at month 3 for all kidney and lumbar embolizations (n = 12/12). Control coils had technical success for 12/12, with a persistent occlusion at month 3 for 2/12. No off-target embolization occurred. ABEA torpedoes demonstrate faster occlusion (ABEA: 6 ± 4 s; coils: 427 ± 469 s; p = 0.0022, n = 12) and preparation times (ABEA: 96.9 1 ± 23 s; coils: 150.33 ± 58 s; p = 0.0432, n = 12) after device placement than coil. No significant difference in inflammation between ABEA and coil groups at month 2 (ABEA: 3.35e ± 1.7e%ID/mm; coils: 2.24e ± 8.5e%ID/mm3; p = 0.5) on PET imaging. These results were confirmed by histological analysis at month 3.
Permanent dry foam torpedo comprising agar-agar is effective for arterial embolization. In animal model, one ABEA torpedo demonstrates a faster and more persistent occlusion than one fiber coil.
Not applicable.
评估一种基于琼脂的环保型永久性动脉内栓塞剂（ABEA）（EmboBio®）的安全性和有效性。
六只猪，分别用一枚ABEA栓塞剂（6条肾下极动脉和6条腰动脉）和一枚弹簧圈（6条肾下极动脉和6条腰动脉）进行栓塞。技术成功定义为DSA显示完全闭塞且无残余血流。短期终点包括安全性（非靶向栓塞）、易用性（栓塞准备时间、闭塞时间）以及术后第7天、1个月和3个月时的DSA检查。在术后第2个月通过[18F]-FDG PET/CT评估组织反应，术后第3个月进行组织学研究。
在术后3个月时，所有肾脏和腰部栓塞（n = 12/12）中，ABEA栓塞剂均实现了即刻且持久的闭塞。对照弹簧圈12/12技术成功，术后3个月时2/12实现持久闭塞。未发生非靶向栓塞。ABEA栓塞剂在装置置入后的闭塞速度（ABEA：6 ± 4秒；弹簧圈：427 ± 469秒；p = 0.0022，n = 12）和准备时间（ABEA：96.91 ± 23秒；弹簧圈：150.33 ± 58秒；p = 0.0432，n = 12）均快于弹簧圈。术后第2个月，PET成像显示ABEA组和弹簧圈组之间炎症无显著差异（ABEA：3.35e ± 1.7e%ID/mm；弹簧圈：2.24e ± 8.5e%ID/mm3；p = 0.5）。这些结果在术后第3个月的组织学分析中得到证实。
含琼脂的永久性干泡沫栓塞剂对动脉栓塞有效。在动物模型中，一枚ABEA栓塞剂比一枚纤维弹簧圈显示出更快且更持久的闭塞效果。
不适用。
